Serum erythropoietin titers in hematological malignancies and related diseases

Urabe, Akio; Mitani, Kinuko; Yoshinaga, Kosuke; Iki, Seiko; Yagisawa, Masako; Ohbayashi, Y; Takaku, Fumimaro

doi:10.1002/stem.5530100604

Cited by 18 publications

(14 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were also obtained in studies abroad, although the EPO levels increased up to~100 mIU/mL in some patients with stage 3 CKD [5,6]. In contrast, EPO levels were >50 mIU/mL in most patients with hematological diseases [3,4].…”

Section: Rationalesupporting

confidence: 87%

“…In these reports, most patients with hematopoietic disorders such as aplastic anemia and myelodysplastic syndromes (MDS) with Hb levels of <10 g/dL showed serum EPO levels of >50 mIU/ mL [by radioimmunoassay or the chemiluminescent enzyme immunoassay (CLEIA)] [3,4], whereas most CKD patients showed serum EPO levels of <50 mIU/mL [by enzyme-linked immunosorbent assay (ELISA) or the CLEIA method] [5,6] (different measurement methods may affect the measured value of EPO, but such an effect has not been examined). Moreover, it has been reported that the increase in EPO level in response to the decrease in Hb level is suppressed at more advanced stages of CKD [6].…”

Section: )mentioning

confidence: 99%

See 1 more Smart Citation

2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

Yamamoto¹,

et al. 2017

View full text Add to dashboard Cite

Section: Rationalesupporting

confidence: 87%

Section: )mentioning

confidence: 99%

2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

Yamamoto¹,

et al. 2017

View full text Add to dashboard Cite

“…In agreement with pre vious studies [4][5][6][7], we found a significant inverse correla tion between the log Epo concentration and haematocrit in patients with acquired AA. Plasma Epo concentrations were much higher in patients with acquired AA than in patients with anaemia of other aetiologies.…”

Section: Discussionsupporting

confidence: 92%

“…Recombinant human Epo has been used as replace ment therapy in patients with impaired production of Epo and as a pharmacologic agent in patients with normal, but insufficient, Epo production [3]. Previous studies have shown that serum Epo concentrations are significantly higher in patients with AA than in normal controls and correlate inversely with haemoglobin concentrations [4][5][6][7], Because plasma Epo concentrations vary considerably among patients with the same haemoglobin concentra tion, we evaluated factors that may influence the Epo con centration in patients with acquired AA. Another aim of the present study was to provide information about the likelihood that patients with acquired AA might benefit from treatment with exogenous Epo.…”

Section: Introductionmentioning

confidence: 99%

Circulating Erythropoietin in Patients with Acquired Aplastic Anaemia

Kojima¹,

Matsuyama²,

Kodera³

1995

Acta Haematol

View full text Add to dashboard Cite

The plasma erythropoietin (Epo) concentration was measured by radioimmunoassay in 75 patients with acquired aplastic anaemia. Overall there was an inverse relationship between the concentration of plasma Epo and the degree of anaemia. Plasma Epo concentrations were lower in patients who were sampled soon after diagnosis as opposed to those studied at later times. Although a decrease in the plasma Epo concentration was noted in all erythroid respond-ers following immunosuppressive (IS) therapy or bone marrow transplantation (BMT), it was lower in patients undergoing BMT than in those receiving IS therapy for any given degree of anaemia.

show abstract

“…It has been observed that, for similar degrees of anemia, patients with aplastic erythroid marrow had higher serum Epo levels than patients with iron deficiency anemia, and even more so compared to patients with megaloblastic anemia or thalassemia intermedia. [18][19][20] It has also been shown that serum Epo levels decreased rapidly on introduction of iron or vitamin B 12 for the treatment of iron deficiency 20 or megaloblastic anemia 20,21 well before any detectable change in hemoglobin. Similarly, we have observed that the kinetics of change of serum Epo levels after autologous hematopoietic stem cell transplantation was clearly dependent on the speed of erythroid engraftment.…”

Section: Discussionmentioning

confidence: 99%

Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia

Piron

Loo

Gothot

et al. 2001

Blood

View full text Add to dashboard Cite

Little information is available on the evolution of erythropoiesis after interruption of recombinant human erythropoietin (rHuEpo) therapy. Iron-overloaded rats received 20 daily injections of rHuEpo. During treatment, reticulocytes, soluble transferrin receptor (sTfR), and hematocrit increased progressively. This was accompanied by a substantial expansion of spleen erythropoiesis but a decrease in the bone marrow. Five weeks after treatment, rats developed a significant degree of aregenerative anemia. Erythropoietic activity, as assessed by reticulocytes, sTfR, erythroid cellularity, iron incorporation into heme, and the number of erythroid colonies, was severely depressed 3 weeks after cessation of rHuEpo. This was followed by regeneration of erythroblasts and reticulocytes at weeks 6 to 7 post-Epo, but erythroid progenitors recovered only partially by that time. The anemia was definitely corrected 2 months after cessation of rHuEpo treatment. Serum Epo levels remained elevated for several weeks, but the sensitivity of marrow erythroid precursors to Epo was preserved. No rat antibodies to rHuEpo were detected, and serum from post-Epo animals did not exert any inhibitory activity on erythropoiesis. In conclusion, after cessation of intensive rHuEpo therapy, there was a strong inhibition of erythropoietic activity with secondary anemia followed by late recovery. This was not due to antibodies or other soluble inhibitory factors, a defect in endogenous Epo production, or a loss of sensitivity to Epo. This may rather represent intrinsic erythroid marrow exhaustion, mostly at the level of erythroid progenitors but also at later stages of erythropoiesis. IntroductionRecombinant human erythropoietin (rHuEpo) has been used extensively to treat the anemia of renal failure and is increasingly considered for use in other situations. 1 In normal subjects, rHuEpo elicited a dose-dependent stimulation of erythropoiesis, resulting in elevated reticulocytes, soluble transferrin receptors (sTfRs), and hematocrit (Hct), 2-5 allowing for the collection of multiple red blood cell units. 6,7 The magnitude of the erythropoietic response was similar in normal subjects, in patients with genetic hemochromatosis, and in patients with the anemia of chronic renal failure. 8 After cessation of treatment, one would expect a gradual return of all erythroid parameters to baseline levels. This has never been studied in normal subjects, except in the setting of surgery and/or autologous blood donation. However, it is obvious that inflammation, bleeding, and transfusions associated with surgery, as well as anemia and iron deficiency associated with phlebotomy will preclude any meaningful interpretation of posttreatment changes in terms of overall erythroid marrow capacity to produce red cells. Therefore, we designed a study in normal rats to examine the long-term evolution of erythropoiesis after stopping intensive treatment with rHuEpo. Surprisingly, we did not simply observe a gradual return to baseline, but rather a diphasic evolution of pr...

show abstract

Serum erythropoietin titers in hematological malignancies and related diseases

Cited by 18 publications

References 10 publications

2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

Circulating Erythropoietin in Patients with Acquired Aplastic Anaemia

Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia

Contact Info

Product

Resources

About